<?xml version="1.0"?>
<oembed><version>1.0</version><provider_name>Frezza Partners</provider_name><provider_url>https://frezzapartners.com/en/</provider_url><author_name>Frezza Partners</author_name><author_url>https://frezzapartners.com/en/author/fr3zz4partn3rs/</author_url><title>AIFA approva il vaccino Nuvaxovid (Novavax) - Frezza Partners</title><type>rich</type><width>600</width><height>338</height><html>&lt;blockquote class="wp-embedded-content" data-secret="Z22QPmxjZN"&gt;&lt;a href="https://frezzapartners.com/en/aifa-approva-il-vaccino-nuvaxovid-novavax/"&gt;AIFA approva il vaccino Nuvaxovid (Novavax)&lt;/a&gt;&lt;/blockquote&gt;&lt;iframe sandbox="allow-scripts" security="restricted" src="https://frezzapartners.com/en/aifa-approva-il-vaccino-nuvaxovid-novavax/embed/#?secret=Z22QPmxjZN" width="600" height="338" title="&#x201C;AIFA approva il vaccino Nuvaxovid (Novavax)&#x201D; &#x2014; Frezza Partners" data-secret="Z22QPmxjZN" frameborder="0" marginwidth="0" marginheight="0" scrolling="no" class="wp-embedded-content"&gt;&lt;/iframe&gt;&lt;script type="text/javascript"&gt;
/* &lt;![CDATA[ */
/*! This file is auto-generated */
!function(d,l){"use strict";l.querySelector&amp;&amp;d.addEventListener&amp;&amp;"undefined"!=typeof URL&amp;&amp;(d.wp=d.wp||{},d.wp.receiveEmbedMessage||(d.wp.receiveEmbedMessage=function(e){var t=e.data;if((t||t.secret||t.message||t.value)&amp;&amp;!/[^a-zA-Z0-9]/.test(t.secret)){for(var s,r,n,a=l.querySelectorAll('iframe[data-secret="'+t.secret+'"]'),o=l.querySelectorAll('blockquote[data-secret="'+t.secret+'"]'),c=new RegExp("^https?:$","i"),i=0;i&lt;o.length;i++)o[i].style.display="none";for(i=0;i&lt;a.length;i++)s=a[i],e.source===s.contentWindow&amp;&amp;(s.removeAttribute("style"),"height"===t.message?(1e3&lt;(r=parseInt(t.value,10))?r=1e3:~~r&lt;200&amp;&amp;(r=200),s.height=r):"link"===t.message&amp;&amp;(r=new URL(s.getAttribute("src")),n=new URL(t.value),c.test(n.protocol))&amp;&amp;n.host===r.host&amp;&amp;l.activeElement===s&amp;&amp;(d.top.location.href=t.value))}},d.addEventListener("message",d.wp.receiveEmbedMessage,!1),l.addEventListener("DOMContentLoaded",function(){for(var e,t,s=l.querySelectorAll("iframe.wp-embedded-content"),r=0;r&lt;s.length;r++)(t=(e=s[r]).getAttribute("data-secret"))||(t=Math.random().toString(36).substring(2,12),e.src+="#?secret="+t,e.setAttribute("data-secret",t)),e.contentWindow.postMessage({message:"ready",secret:t},"*")},!1)))}(window,document);
//# sourceURL=https://frezzapartners.com/wp-includes/js/wp-embed.min.js
/* ]]&gt; */
&lt;/script&gt;
</html><thumbnail_url>https://frezzapartners.com/wp-content/uploads/2021/12/pexels-nataliya-vaitkevich-5863316-scaled.jpg</thumbnail_url><thumbnail_width>2560</thumbnail_width><thumbnail_height>1707</thumbnail_height><description>photo by Natalyia Vaitkevic &nbsp; La Commissione Tecnico Scientifica (CTS) di AIFA, nella riunione del 22 dicembre 2021, ha approvato l&#x2019;utilizzo del vaccino Nuvaxovid (Novavax), rendendolo disponibile nell&#x2019;intera indicazione autorizzata da EMA per i soggetti di et&#xE0; uguale o superiore ai 18 anni. La vaccinazione prevede un ciclo vaccinale primario di due dosi a distanza di tre settimane l&#x2019;una dall&#x2019;altra. I dati disponibili, rileva la CTS, sul vaccino Nuvaxovid hanno mostrato una efficacia di circa il 90% nel prevenire la...</description></oembed>
